التداخل بين لاباتينيب وباكليتاكسيل

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%.

This increase in paclitaxel exposure may have been underestimated from the in vivo evaluation due to study design limitations.